Research library

SS-31 Research Overview: Cardiolipin-Targeted Mitochondrial Pharmacology and Trial Evidence

Compiled by:: Peptide Pilots Scientific Content Team
Reviewed by:: Peptide Pilots Quality & Compliance review
Last revised:: 3 September 2026

What has SS-31 (elamipretide) actually shown in human trials, and where has it fallen short of its endpoints?

SS-31 is a small, cell-permeable aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, reported to stabilise cristae structure and electron-transport-chain organisation. In-vitro and animal studies report reduced reactive oxygen species and preserved ATP production across ischaemia-reperfusion, heart-failure and muscular-dystrophy models. Under the clinical name elamipretide, it has been tested in several randomised human trials; results have been mixed, with the phase 3 Barth syndrome trial (TAZPOWER) not meeting its primary six-minute-walk endpoint despite some secondary-measure improvements, and other indications (primary mitochondrial myopathy, heart failure with preserved ejection fraction, dry age-related macular degeneration) also reporting inconsistent or negative primary results.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is SS-31 (Elamipretide)?

SS-31 belongs to the Szeto-Schiller family of aromatic-cationic peptides, four residues in length with alternating basic and aromatic side chains, designed to selectively accumulate in mitochondria independent of membrane potential.

In laboratory work it is used as a tool compound to probe cardiolipin-dependent mitochondrial membrane organisation and as a candidate therapeutic (elamipretide) evaluated in genetic and acquired mitochondrial-dysfunction conditions.

SS-31 (Elamipretide) names and identifiers

Also referred to as: Elamipretide; MTP-131; Bendavia; D-Arg-2',6'-Dmt-Lys-Phe-NH2

Sequence	D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2
Molecular formula	C36H49N9O5
Average molecular weight	≈639.8 g/mol
Clinical development code	MTP-131 / elamipretide
Proposed molecular target	Cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane
Registry records	ClinicalTrials.gov NCT03098797 (TAZPOWER, Barth syndrome), NCT03323749 (myopathy), NCT03422640 (HFpEF)

SS-31 (Elamipretide) research background

The Szeto-Schiller peptides were developed in the early 2000s from opioid-peptide-derived scaffolds selected for mitochondrial accumulation rather than opioid activity, with SS-31 emerging as the lead compound after structure-activity work on antioxidant and cytoprotective effects.

Subsequent biophysical studies proposed cardiolipin binding, rather than direct radical scavenging, as the primary mechanism, since cardiolipin organises cristae architecture and anchors electron-transport-chain complexes and cytochrome c.

Stealth BioTherapeutics advanced the compound as elamipretide into clinical development for Barth syndrome, primary mitochondrial myopathy, heart failure with preserved ejection fraction and dry age-related macular degeneration; the Barth syndrome programme is the most extensively published human dataset.

Proposed SS-31 (Elamipretide) mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

SS-31 (Elamipretide) in-vitro and cell-based evidence

Selectively partitions into the inner mitochondrial membrane through electrostatic and hydrophobic interaction with cardiolipin, independent of the mitochondrial membrane potential that drives accumulation of many other cationic compounds.
Reported to prevent cardiolipin peroxidation and cytochrome c dissociation, preserving electron-transport-chain supercomplex assembly and reducing reactive oxygen species generation in isolated mitochondria and cultured cells under oxidative stress.
Studies report improved ATP synthesis efficiency in cardiolipin-deficient (tafazzin-mutant) cell models, providing mechanistic rationale for testing in Barth syndrome.

SS-31 (Elamipretide) animal-model evidence

Rodent ischaemia-reperfusion models of heart and kidney report reduced infarct size and preserved mitochondrial respiration with peri-procedural administration.
Aged and dystrophic mouse muscle models report improved mitochondrial morphology and some functional muscle measures.
Tafazzin-knockdown and Barth-syndrome mouse models report partial correction of cardiolipin abnormalities and cardiac mitochondrial function.

Published SS-31 (Elamipretide) human-study evidence

The phase 2/3 TAZPOWER trial in Barth syndrome (subcutaneous elamipretide) did not meet its primary six-minute-walk-distance endpoint in the randomised withdrawal phase, though some secondary measures (muscle strength) showed differences favouring treatment.
A phase 3 trial in primary mitochondrial myopathy (MMPOWER-3) did not meet its co-primary six-minute-walk and fatigue endpoints.
A phase 2 trial in heart failure with preserved ejection fraction reported no significant improvement on the primary functional endpoint.
An intravitreal reformulation studied in geographic atrophy (dry AMD) did not meet its primary lesion-growth endpoint in phase 3 (ReCLAIM-2).

Published SS-31 (Elamipretide) studies

Selected published studies involving SS-31 (Elamipretide)
Study	Model / type	Research question	Main observation	Citation
Szeto & Schiller, mechanistic review	Review of biophysical and cell-based cardiolipin-binding data	What is the proposed molecular basis for SS-peptide mitochondrial protection?	Describes selective cardiolipin binding and cristae stabilisation as the mechanistic basis distinguishing this peptide class from general antioxidants.	Clinical Pharmacology & Therapeutics, 2014
Thompson et al., TAZPOWER trial	Human, randomised placebo-controlled and open-label extension, Barth syndrome	Does subcutaneous elamipretide improve functional capacity in Barth syndrome?	Primary six-minute-walk endpoint not met in the randomised withdrawal phase; secondary muscle-strength measures showed differences favouring treatment.	Genetics in Medicine, 2021
Karaa et al., MMPOWER-3 trial	Human, randomised placebo-controlled, primary mitochondrial myopathy	Does elamipretide improve walk distance and fatigue in mitochondrial myopathy?	Co-primary endpoints (six-minute-walk distance and fatigue score) were not met.	Journal of Cachexia, Sarcopenia and Muscle, 2021
ReCLAIM-2 trial	Human, randomised placebo-controlled, geographic atrophy	Does intravitreal elamipretide slow lesion growth in dry age-related macular degeneration?	Primary endpoint of reduced geographic-atrophy lesion growth was not met.	ClinicalTrials.gov registry summary, NCT03891875, 2022

Limitations of the SS-31 (Elamipretide) evidence

Despite consistent preclinical mechanistic and animal efficacy signals, the corresponding phase 3 human trials across several indications (Barth syndrome, primary mitochondrial myopathy, dry AMD) have not met their primary endpoints, illustrating a substantial translational gap.
Positive findings in the human programme are largely confined to secondary or exploratory endpoints and open-label extension data, which are more prone to bias than the negative randomised primary results.
Subcutaneous administration in trials has been associated with injection-site reactions, which complicates blinding and adherence in some studies.
Cardiolipin-binding as the operative mechanism is inferred mainly from biophysical and cell-based work; a fully validated in-vivo target-engagement biomarker for human dosing is not established in the published literature.
Most large trials are sponsor-conducted (Stealth BioTherapeutics), and independent replication of the positive secondary findings is limited.

SS-31 (Elamipretide) laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

Appearance	White to off-white lyophilised powder
Solubility	Water-soluble; a small, highly polar cationic tetrapeptide
Lyophilised storage	Commonly stored at −20 °C, desiccated and protected from light
Reconstituted handling	Kept cold and used within a short window in research protocols to limit degradation
Analytical testing	RP-HPLC purity and MS identity are standard checks for a peptide of this size
Stability considerations	As a short amidated peptide it is relatively stable, though oxidation of the dimethyltyrosine residue is monitored in formulation work

Frequently asked SS-31 (Elamipretide) research questions

Is SS-31 the same substance as elamipretide?

Yes. SS-31 is the original research designation; elamipretide (also coded MTP-131, tradename Bendavia in some development programmes) refers to the same peptide advanced through clinical trials.

What does 'cardiolipin-targeted' mean in this context?

It refers to the peptide's proposed binding to cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane that organises cristae structure and anchors respiratory-chain complexes, rather than acting as a generic free-radical scavenger.

Did the Barth syndrome trial succeed?

The phase 2/3 TAZPOWER trial did not meet its primary six-minute-walk-distance endpoint in the randomised withdrawal phase, although some secondary muscle-strength measures favoured treatment.

Have other indications been more successful?

Published phase 3 results in primary mitochondrial myopathy and geographic atrophy also did not meet their primary endpoints, so the human trial record across indications is mixed rather than confirmatory.

SS-31 (Elamipretide) primary references

Szeto HH, Birk AV (2014). Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2014.183
Thompson WR, Hornby B, Manuel R, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. https://doi.org/10.1038/s41436-021-01125-0
Karaa A, Haas R, Goldstein A, et al. (2021). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12746
Stealth BioTherapeutics (2022). ReCLAIM-2 phase 3 study of elamipretide in geographic atrophy secondary to age-related macular degeneration. ClinicalTrials.gov registry summary, NCT03891875. https://clinicaltrials.gov/study/NCT03891875

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published 22 August 2026; last revised 3 September 2026. Pages are revised when the cited literature changes materially.